What Is Small Lymphocytic Lymphoma? Small lymphocytic lymphoma (SLL) is a cancer that affects a type of white blood cell called a "lymphocyte," which helps your body fight infection. You may hear ...

Apr. 4, 2025 — A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated ...

B-cell lymphoma is a type of blood cancer that affects the B lymphocytes of the immune system. They usually arise in the lymph nodes or in other lymphoid tissue, such as the spleen, bone marrow ...

Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) occurs when lymphocytes called T cells and B cells become ...

Follicular lymphoma is a ... uses a needle to remove a small amount of liquid bone marrow. Your doctor will look at the sample under a microscope and check for sick cells to see if the disease ...

T-cell lymphomas are a type of non-Hodgkin lymphoma that involve the malignant transformation of T cells. Four major types have been characterized: extranodal T-cell lymphoma, cutaneous T-cell ...

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for extensive-stage small cell lung cancer. Early trial results show combining the ...

These findings suggest this unique cell therapy approach has promise for specific patients with lymphoma, but it may be adapted for more cancer types in the future. "We observed rapid and strong ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody ... and open up opportunities ...

Success in this trial could lead to further studies and potential accelerated registration strategies for this underserved patient population. The first patient with small cell lung cancer has been ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.